Elanco

19/09/2024

This is the moment we have been itching for! Today, we announced the U.S. Food and Drug Administration (FDA) has approved Zenrelia™ (ilunocitinib tablets), a safe, highly effective, and convenient once-daily oral JAK inhibitor for control of pruritus (itching) associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. Itching is one of the top reasons pet owners bring their dogs to the veterinarian with approximately 17 million dogs in the U.S. suffering from allergic skin disease, including atopic dermatitis, food allergies or flea sensitivity.(1)

The approval of Zenrelia represents an important advancement in treating itchy dogs suffering from chronic, acute or seasonal itch and inflammation in a single, once daily tablet from the start.

Today’s announcement makes us just the second animal health company, with a comprehensive portfolio including parasiticides, vaccines, pain and other therapeutics, and now, dermatology.

Read more here: https://bit.ly/Zenrelia



Sources:
(1)AVMA Sourcebook. Elanco, Dermatology Products SOV Study, 2023

See package insert including the Boxed Warning. For full prescribing information speak with your veterinarian, call 1 888 545 5973 or visit www.elancolabels.com/us/zenrelia.

WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease and inadequate immune response to vaccines. Dogs should not take Zenrelia for a time period before and after vaccination. Discuss your dog’s vaccine schedule with your veterinarian.

18/09/2024

Bei Elanco findet jedes Jahr der Global Day of Purpose statt. Ein Tag, den die Mitarbeiter:innen weltweit bei Elanco nutzen können, um sich aktiv bei sozialen Projekten zum Wohle von Tieren, Menschen und des Planeten zu engagieren.

So haben alleine unsere Kolleg:innen der Elanco-Standorte in Deutschland, Österreich und der Schweiz 2023 mehr als 3.000 Stunden ehrenamtliche Arbeit in verschiedenen Projekten geleistet. Ob es die tatkräftige Hilfe bei Auf- und Abbau der Spendengala für VITA e.V. Assistenzhunde, die Renovierung eines Tierheims, das Sammeln von mehr als 3.000 Litern Müll am Strand und im Wald oder bei einem Wohltätigkeitslauf für eine lokale Tierschutzorganisation war: Soziales Engagement und Nachhaltigkeit sind für Elanco Grundpfeiler der Unternehmenskultur.

Daher sind für uns Initiativen wie die Deutschen Aktionstage Nachhaltigkeit ein Ansporn für die Elanco-Engagements zum Global Day of Purpose 2024.

Weitere Infos: www.elanco.com/de-de/sustainability

17/09/2024

Each year, an estimated 330,000(1) dogs are diagnosed with canine parvovirus — one of the deadliest viruses a dog can contract — resulting in up to a 91%(2) mortality rate without supportive care. A patient with parvovirus can be exhausting and stressful for clinic staff. But with our USDA-conditionally approved Canine Parvovirus Monoclonal Antibody, veterinarians are seeing real, effective results.


1: Elanco. Data on File.
2: Venn EC, JVET Emerg Crit Care. 2017.

16/09/2024

Our pets are part of our families and veterinarians know that firsthand. For Dr. Emily Swiniarski, Medical Director of Anti-Cruelty, and Dr. Amanda Schnitker, Hospital Director at Companion Animal Hospital River North and Uptown Animal Hospital, the bond between pet owners and their pets is what makes this profession so rewarding, despite its complexities.

In the latest Shared Table newsletter, Jeff Simmons, President and CEO, sits down with Drs. Swiniarski and Schnitker to discuss their career journeys, how the industry has changed after the COVID-19 pandemic and the many existing challenges veterinarians face every day.

Learn more and watch the full episode here: https://bit.ly/SharedTableVets

12/09/2024

From Australia to Brazil, our global team is making their presence known. Recently, our Australian pet team attended the Australian Small Animal Veterinarians and Veterinary Business Group conference. With more than 350 veterinarians, this has become one of the region’s most comprehensive small animal conferences. The team featured an interactive exhibition booth for veterinary professionals to learn about our innovative animal health solutions.

In Brazil, the swine team attended the Southern Brazilian Swine Symposium. In addition to connecting with customers at our booth, Isis Mariana Pasian, Technical Consultant, presented on ensuring farm rodent control. This event reinforced our contribution to the swine industry’s development with effective solutions.

12/09/2024

At the 66th General Assembly of , the EU association of
poultry meat producers, in Bruges, Belgium, stakeholders and members of
the poultry industry discussed topics concerning the future of economic and
sustainable developments in the poultry sector. The topics discussed at the
event underlined the fact that current geopolitical changes are also having a
major impact on the poultry sector. This is an aspect that AVEC and its
partners take into account when working towards a sustainable and futureoriented
poultry industry.
avec-bruges.be
x.com/avecpoultry?mx=2

06/09/2024

Intestinal tapeworms are a real threat for both dogs and humans. These worms can easily be transmitted from your pet to you, taking exposure from "ick" to "sick". Dr. Elise Kelly, Elanco Senior Regional Consulting Veterinarian, joined MyFox28 Columbus to discuss the risks and symptoms of tapeworms, how dogs can contract them and the importance of year-round protection.

https://bit.ly/4gdxgzc

05/09/2024

25,000. That’s how many hours our global team has committed to volunteering by 2025. Last year, our team recorded more than 23,600 volunteer hours supporting causes to improve animal welfare, community services, food security and education worldwide. But that’s just the start. Officially one month out from our annual Global Day of Purpose- an event to kick off a month of giving and volunteerism- our team is gearing up to make this year our biggest yet!

03/09/2024

Canine parvovirus is one of the most contagious and deadly viruses for dogs and puppies. Until recently, the only treatment was supportive care. That changed with our USDA-conditionally approved Canine Parvovirus Monoclonal Antibody (CPMA). Now, veterinarians, pet owners and puppies have a chance to fight back against this deadly disease.
📸 1: CPMA-treated parvo survivor Mia, 4 months from Woodstock, IL, Helping Paws Animal Shelter
📸 2: CPMA-treated parvo survivor Spaz, 3 months old from Papillion, NE, Papillion Animal Hospital
📸 3: CPMA-treated parvo survivor Yeti, 3 months old from San Leon, TX, Bay Area Pet Adoptions

29/08/2024

Up to 900 dogs are diagnosed with canine parvovirus each day.(1) When left untreated, this disease has a mortality rate of up to 91%.(2) But with the USDA-conditionally approved Canine Parvovirus Monoclonal Antibody (CPMA), we’re changing the game. Based on real world usage, 93% of patients treated with CPMA survived.(3)

📸 1: CPMA-treated parvo survivor Walter Danahue, 3 months old from San Diego, CA, Tell Tail Veterinary Urgent Care
📸 2: CPMA-treated parvo survivor Charlie, 3 months old from Wesley Chapel, FL, Seven Oaks Pet Hospital
📸 3: CPMA-treated parvo survivor Mabel, 3 months old from Mattoon, IL, Albin Animal Hospital



1: Elanco Animal Health. Data on file.
2: Venn EC, JVET Emerg Crit Care. 2017.
3: Elanco. Market Data on file.

28/08/2024

Did you know that 30% of UK vets have seen at least 1 death from lungworm in the last 5 years?*

Administering monthly lungworm prevention can protect dogs from infection.

Check common risk factors and symptoms on https://bit.ly/4fWPUeG .

27/08/2024

Saving puppies and creating jobs – we can’t think of a better reason to celebrate. Our Elwood, Kansas manufacturing site produces and ships our Canine Parvovirus Monoclonal Antibody – the first and only USDA conditionally approved, targeted treatment for canine parvovirus. And we’re just getting started.
We unveiled plans for the expansion of our specialized manufacturing facility in Elwood, bringing together “the three P’s” of what truly sets us apart.
👷People: This 25,000 sq. ft. expansion project will double our production capacity and create approximately 70 new jobs by 2026.
🐶 Purpose: We’re serious about getting puppies back to playtime. We are one of only two animal health companies with monoclonal antibody treatments on the market, and the only one with a treatment for parvovirus, which has a high mortality rate, primarily affecting puppies.
📈 Potential: Drawing insights from advancements in human health, the animal health sector is focusing on antibody-based therapies. As this new market expands, our Elwood facility is poised to meet those demands to provide veterinarians and pet parents new solutions for persistent problems.
Thank you to Kansas Lt. Governor Toland and Senator Moran, the State of Kansas, the many staff of the Kansas Department of Commerce, local civic leaders in Elwood, the City of Elwood and Doniphan County, Kimberly Young and the entire Kansas City Animal Health Corridor team, and Evergy for their partnership. We look forward to our partnership with the Burns and McDonnell team leading the expansion as the primary provider of integrated design and construction services.
Here’s to this next era of innovation!

26/08/2024

Canine parvovirus kills. But with the USDA-conditionally approved Canine Parvovirus Monoclonal Antibody (CPMA), we’re fighting back. Across the U.S. more than 27,000 puppies have been saved by CPMA(1), giving puppies a second chance at life.
📸 1: CPMA-treated parvo survivor Sitka, 2 months old from New Tazewell, TN, Claiborne Animal Shelter
📸 2: CPMA-treated parvo survivor Cooper, 3 months old from Ila, GA, Ila Vet Clinic.
📸 3: CPMA-treated parvo survivor Indy, 2 months old from Myrtle Beach, SC, Hometown Veterinary Partners
📸 4: CPMA-treated parvo survivor Oats, 3 months old from Papillion, NE, Papillion Animal Hospital.

1: Elanco Animal Health. Data on file.

23/08/2024

Meet Noah Brown, the first technical apprentice paving the way for the new "Earn to Learn" manufacturing program at our Clinton, Indiana facility. For more than 50 years, this site has had a long history of innovation and delivering products while remaining interconnected to the community. At times, there have even been three generations of a family going to work together.

This latest partnership with Ivy Tech Community College aims to build upon the community legacy by using top talent in the area. Participants in the “Earn to Learn” program will earn full-time wages while they work towards a Technical Certificate in the mechanical field. This program opens doors for people to gain valuable skills and real-world experience, all while helping advance our purpose of making life better.

21/08/2024

Our team’s commitment to animal health extends beyond their daily job through the entire industry. Dr. Claudia Osorio, Farm Animal Associate Advisor, was recently elected as President of the American Association of Avian Pathologists (AAAP). The AAAP is an international association with the mission to promote scientific knowledge to enhance the health, well–being and productivity of poultry to provide safe and abundant food for the world. With more than 17 years in the field, this achievement demonstrates Dr. Osorio’s commitment to poultry disease prevention and enhancing poultry health.

20/08/2024

Today, we announced a 25,000-square-foot expansion of our biologics manufacturing facility in Elwood, Kansas. This new investment will enable further growth in our monoclonal antibody (mAb) platform, building on the robust expertise already present at the facility. The animal health sector is increasingly focusing on antibody-based therapies, drawing insights from advancements in human health. These therapies are recognized for their effectiveness and the potential for faster resolution of clinical signs or severe disease. They will be fundamental in enhancing the quality of life for pets and strengthening the human-animal bond. Burns and McDonnell is serving as the design-build partner on this project.
Learn more: https://bit.ly/3SVXT1F

20/08/2024

🚨Exciting Innovation Update🚨
Our era of innovation continues. Today, we announced that Credelio Quattro, our broad-spectrum parasiticide, is moving to the Food and Drug Administration (FDA) final 60-day administrative review phase. U.S. approval is expected in October 2024 and launch expected in Q1 2025.
We now expect to launch a potential blockbuster each of the next three quarters in large, fast-growing or new markets that are largely accretive to Elanco:
- Q3 2024: Bovaer, the only FDA-reviewed feed ingredient with a methane-reduction claim, launching in the U.S. dairy market
- Q4 2024: Zenrelia, our JAK inhibitor, launching in the fast-growing canine dermatology market
- Q1 2025: Credelio Quattro, our broad-spectrum parasiticide, launching in the largest pet health market
We continue to expect $600 million to $700 million of innovation sales in 2025.

“We are very pleased with the continued progress of our pipeline,” said Dr. Ellen de Brabander, Executive Vice President of Innovation and Regulatory Affairs. “We completed the Bovaer review ahead of schedule and now have two potential blockbusters – Zenrelia and Credelio Quattro – in the final administrative review at FDA, illustrating our R&D organization’s high capacity and ability to build capabilities to deliver a consistent flow of high impact innovation. A significant thank you to the Elanco team for their efforts to bring these differentiated innovations toward approval while also refilling and advancing the early-stage pipeline for the next era of innovation.”

Read more here:

Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Food and Drug Administration (FDA) has completed its review of all major and minor technical sections for Credelio Quattro, and the final 60-day administrative review is underway.

19/08/2024

The animal health market is a rapidly growing industry with a global market value estimated at $60 billion. Tim Bettington, EVP of Corporate Strategy and Market Development, joined the AgriNovus Indiana Agbioscience podcast to discuss the evolution of animal health, the forces driving its growth and how we are approaching the next wave of innovation. With three potential blockbusters on the horizon, Tim shares the challenges and opportunities of bringing new innovation to both pet and farm animal markets.
Listen to the episode here: https://bit.ly/3Avdb78

16/08/2024

Whether it’s a family meal, a team meeting or just old friends catching up, real connection begins around the table. Inspired by the power of coming together in this way, our President and CEO, Jeff Simmons, launched Shared Table, a monthly LinkedIn Newsletter that covers the real conversations he's having with animal health industry leaders on big topics from climate and sustainability to access to pet care to the challenges of leading in a post-COVID world.

In the first newsletter, Jeff sits down with Frank Mitloehner, Ph.D., Director, UC Davis CLEAR Center, Department of Animal Science to discuss livestock and their role in climate and sustainability. Watch "Trust, Cows, Milk and Climate" as the two talk about the latest innovative solutions in the dairy industry, how the cow can be part of the how to reduce climate warming and the path to climate neutral animal agriculture farms in this decade.
Watch the full episode here: https://bit.ly/4dIRxdQ

16/08/2024

Was das One Health-Konzept für uns als globales Tiergesundheitsunternehmen mit Forschungs- und Entwicklungsstandorten auch in Deutschland bedeutet, hat unser Kollege Tierarzt Dr. Stefan Pachnicke, Leitung Tierärztliche Fachabteilung bei der Elanco Deutschland GmbH, vor Kurzem im Interview erklärt, das auch in einer Beilage der Zeitung „Die Welt“ enthalten war.

Darin weist er vor allem auch auf die Bedeutung von Zoonosen – also Erreger an denen Menschen und Tiere gleichermaßen erkranken können – für Haustierhalter:innen und ihre Vierbeiner hin. Die nachhaltige Bekämpfung dieser Erreger, z.B. auch übertragen durch Zecken, Flöhe und Mücken, spielen im One Health-Konzept eine herausragende Rolle, denn es geht um eine gesamtgesundheitliche Betrachtung, also „One Health – eine Gesundheit“.
Unsere Lese-Empfehlung: https://bit.ly/3AnBgg2

15/08/2024

When it comes to protecting our dogs from ticks, time is of the essence. In a recent head-to-head study published in Parasites & Vectors, it was found that the aggressive lone star tick is no match for Credelio® (lotilaner), a prescription flea and tick protection product from Elanco. The study compared three popular prescription flea and tick treatment products for dogs, Credelio, Simparica TRIO® (sarolaner, moxidectin, pyrantel), and NexGard® (afoxolaner) with a conclusion that Credelio kills ticks* 2x as fast as Simparica TRIO and NexGard.(1, 2) Understanding the significance of speed of kill is vital when it comes to protecting pets, and Credelio stands out with its swift action against ticks*, ensuring a rapid and effective kill to minimize potential health risks.
Learn more: https://bit.ly/3SRzREN


1. Reif KE, Kollasch TM, Neilson JC, Herrin BH, Ryan WG, Bell MC, Beltz MS, Dryden MW, Jesudoss Chelladurai JRJ, Miller KR, Sutherland CJ. Comparative speed of kill provided by lotilaner (Credelio™), sarolaner (Simparica Trio™), and afoxolaner (NexGard™) to control Amblyomma americanum infestations on dogs. Parasit Vectors. 2024 Jul 20;17(1):313.
2. Based on the time to statistical significance vs control in a single study against NexGard and Simparica Trio on days 21 and 28 for
reinfestations.

*Amblyomma americanum (lone star tick)

14/08/2024

Shaping the future of animal health through the Elanco Scholar's Program. This new initiative links individuals within our talent programs as interns, post-doctoral scientists and fellows with additional training, networking and career development opportunities. The newest component is “Elanco’s Animal Health Fellowships,” which supports areas of external research vital to the animal health industry, increases access to graduate-level training for diverse populations of students and establishes Elanco as an employer of choice for early and diverse talent.
This year, we’ve partnered with four students from Auburn University College of Veterinary Medicine and the Cornell University College of Agriculture and Life Sciences.
🎓Xiaolei Ma, Auburn University, used machine learning capabilities to successfully predict the biological age of dogs based on their gut microbiomes. This groundbreaking work has practical applications for diagnosing and monitoring nutritional adequacy and gut health.
🎓Maria Rebeca Villalobos, Cornell University, aims to gain new perspectives to improve dairy production and enhance sustainability on dairy farms. She aspires to work in precision dairy farming, exploring innovative solutions to optimize efficiency, minimize environmental impact and elevate animal welfare standards.
🎓Dr. Subarna Barua, Auburn University, is studying Biomedical Sciences with research focused on feline coronavirus (FCoV), driving her dedication to improving animal health.
🎓Alexandria Carol Benoit, Cornell University, is conducting research on the integration between amino acids and fatty acids to improve milk component synthesis and overall production efficiency.
Learn more about our Elanco Scholar Program by joining our R&D Talent Community: https://bit.ly/3YzdOqh

12/08/2024

“It’s not about eating, it's about the process of making it…it's very involved and you need a lot of hands…” - Jose Fuxa

Our Manufacturing and Quality interns learned that delicious things can happen when they work together at their third annual Paella Cookoff. This years’ 29 interns from 13 universities seasoned their valuable contributions to engineering, technical services, supply chain and quality teams with one final challenge – working together to create masterful paellas under the tutelage of Elanco’s Executive Director APAC Manufacturing, Jose Fuxa. Never has a life lesson – don't be afraid to try new things together – had so much sizzle.

06/08/2024

The bond between humans and their pets is strengthened through interaction, and for some pets and pet owners, it begins at the local shelter. Last week, members of our Clinton Process Automation Engineering Team volunteered at the local humane shelter to clean up the property, making a more welcoming area for future pet parents to interact with adoptable pets. By improving the environment where these first connections are made, we’re helping pets find a loving home.

02/08/2024

Approximately one in ten adopted pets worldwide leave their adoptive home within six months. Adopting from shelters helps reduce the number of animals euthanized by giving the animal a home and freeing shelter space for others in need. In 2023, our Elanco Brazil team launched the Cãobinado app as part of their responsible adoption initiative. This app helps potential pet owners match with their perfect pet based on lifestyle, home, habits and needs. With more than 220 subscribers and two animal shelters piloting the program, we hope to expand the app to more regions and animal shelters across Brazil.